Title:
RIVASTIGMINE-CONTAINING SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2016/175546
Kind Code:
A2
Abstract:
The present invention relates to a rivastigmine-containing sustained-release pharmaceutical composition and, more specifically, to a rivastigmine-containing sustained-release pharmaceutical composition, which is a sustained-release preparation containing a pH-dependent delayed release phase, wherein, by controlling the release of the pharmaceutical composition to be minimized in the stomach at the initial stage of administration, the pharmaceutical composition can lower the maximum blood concentration (Cmax) compared with existing products while arriving at an effective blood concentration, thereby reducing side effects, and thereafter, maintaining the effective blood concentration through the sustained-release of main ingredients. As a result, the pharmaceutical composition according to the present invention exhibits the same effect as in the existing twice-a-day dosing through only the once-a-day dosing, and can increase the treatment efficiency of patients through the improvement in the convenience of administration of patients.
Inventors:
PARK SANG GEUN (KR)
SHIN HYE GYEONG (KR)
BAE JEONG WOO (KR)
CHOI HYUN JU (KR)
SHIN HYE GYEONG (KR)
BAE JEONG WOO (KR)
CHOI HYUN JU (KR)
Application Number:
PCT/KR2016/004380
Publication Date:
November 03, 2016
Filing Date:
April 27, 2016
Export Citation:
Assignee:
NAVIPHARM CO LTD (KR)
International Classes:
A61K9/00; A61K9/16; A61K31/27; A61K47/30
Other References:
See references of EP 3290023A4
Attorney, Agent or Firm:
GHONG-GAN INTERNATIONAL PATENT LAW FIRM (KR)
특허법인 공간 (KR)
특허법인 공간 (KR)
Download PDF: